Home Clinical development Phase I

Phase I

Phase I

What to Expect at AACR: Long-term Outcomes for Sotorasib in KRAS G12C-mutated NSCLC

Editorial Team - April 7, 2022

First Pateint Dosed with Allogeneic, off-the-shelf, Invariant Natural Killer T-cell Therapy

TRPH-222, a Novel ADC, Shows Positive Results in the Treatment of B-cell non-Hodgkin’s lymphoma

Interleukin-7 Revs up the Immune System Against Glioblastoma

Thoughtful young women suffering from ovarian cancer.

Study Shows 33% Objective Response Rate with STRO-002 in Patients with Advanced Ovarian Cancer

Lasofoxifene Alone or Combined with a CDK Inhibitor may Limits Progression...

Editorial Team - January 11, 2022

Rain Therapeutics and Roche to Study Milademetan + Anti-PD-L1 Immunotherapy in...

Editorial Team - January 7, 2022

Genetically Modified Gamma-Delta T-Cell Therapy in Newly Diagnosed Glioblastoma Multiforme

Editorial Team - January 6, 2022

Low magnification micrograph of mantle cell lymphoma of the terminal ileum. Endoscopic biopsy. H&E stain. Photo Courtesy: 2020. Nephron. This file is licensed under the Creative Commons Attribution-Share Alike 3.0 Unported license.

U.S. FDA approves Phase 3 Study Design for Zilovertamab in the...

Editorial Team - January 4, 2022

Novel Personalized Targeted T-cell Immunotherapy may Facilitate Treatment of Medulloblastoma

Editorial Team - November 18, 2021

A friendly doctor holding a patient's hand sitting at her desk for encouragement, empathy and support following a medical examination.

The Path Toward Curative Treatments in Cervical Cancer

Jennifer Buell, Ph.D. - October 18, 2021

Nader Sanai, MD, an internationally-recognized neurosurgical oncologist with clinical and research expertise in the treatment of all brain tumors and director of the Ivy Brain Tumor Center in Phoenix, Arizona, and a member of his clinical development team.

First-in-human Phase 0/1 Study of Non-Invasive Sonodynamic Therapy Shows Positive Results

Editorial Team - September 21, 2021

General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

Adagrasib Shows Positive Results as Monotherapy and in Combination with Cetuximab...

Editorial Team - September 20, 2021

General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2021: CT041, A New CAR-T for the Treatment of in...

Editorial Team - September 19, 2021

Featured Image: Genmab's Hybridoma and tissue Culture Laboratory. Photo courtesy: 2020 Genmab

Study: Manageable Safety of Epcoritamab in Heavily Pretreated B-Cell Non-Hodgkin Lymphoma

Editorial Team - September 16, 2021

12 3 Page 1 of 3

LATEST NEWS

Combating Financial Hurdles: Setting up Physicians for Short- and Long-term Financial Success

Charlie Nemes - May 18, 2022

Researchers Identify a New Subset of High-risk Pediatric Liver Cancer

Peter Hofland, Ph.D - May 17, 2022

Polypharmacy – How Cancer Patients Face Higher Risks of Drug Interactions

Leslie Orr - May 16, 2022

Study: Isatuximab Combination Provides Unprecedented Median PFS in Treatment of Multiple Myeloma

Peter Hofland, Ph.D - May 15, 2022

Bioimpedance Spectroscopy Better than Tape Measure for Preventing Breast Cancer-Related Lymphedema

Sheila Ridner, PhD, RN, FAAN - May 13, 2022

Press Releases | Cancer

VerImmune and Fosun Pharma enter into an Exclusive License and Option... May 20, 2022
•Novel Anti-tumor Immune Redirection Virus-inspired Particle (AIR-ViP) cancer immunotherapies initially to be developed by VerImmune Inc. •Fosun Pharma to lead clinical development and...(PRWeb May 20, 2022)Read the full story at https://www.prweb.com/releases/verimmune_and_fosun_pharma_enter_into_an_exclusive_license_and_option_agreement_for_verimmunes_virus_inspired_particle_vip_platform_as_novel_immunotherapies_in_china/prweb18690647.htm
New global coalition launched to increase access to, and the use of... May 20, 2022
ASCP co-founds global health initiative to improve cancer diagnosis and treatment of cancer(PRWeb May 20, 2022)Read the full story at https://www.prweb.com/releases/new_global_coalition_launched_to_increase_access_to_and_the_use_of_essential_cancer_medicines_in_low_and_lower_middle_income_countries/prweb18694556.htm
SITC Announces Keynote Speaker Dr. Padmanee Sharma and Keynote Panel... May 19, 2022
This year Society for Immunotherapy of Cancer (SITC) has the pleasure of welcoming Padmanee Sharma, MD, PhD from The University of Texas MD Anderson Cancer Center as the Keynote Speaker at its 37th...(PRWeb May 19, 2022)Read the full story at https://www.prweb.com/releases/sitc_announces_keynote_speaker_dr_padmanee_sharma_and_keynote_panel_honoring_the_work_of_dr_zelig_esshar_at_its_37th_annual_meeting/prweb18689306.htm